全文获取类型
收费全文 | 3474篇 |
免费 | 241篇 |
专业分类
3715篇 |
出版年
2022年 | 20篇 |
2021年 | 41篇 |
2020年 | 22篇 |
2019年 | 19篇 |
2018年 | 39篇 |
2017年 | 36篇 |
2016年 | 77篇 |
2015年 | 97篇 |
2014年 | 125篇 |
2013年 | 239篇 |
2012年 | 183篇 |
2011年 | 184篇 |
2010年 | 116篇 |
2009年 | 112篇 |
2008年 | 180篇 |
2007年 | 199篇 |
2006年 | 168篇 |
2005年 | 177篇 |
2004年 | 191篇 |
2003年 | 185篇 |
2002年 | 150篇 |
2001年 | 114篇 |
2000年 | 110篇 |
1999年 | 101篇 |
1998年 | 42篇 |
1997年 | 34篇 |
1996年 | 28篇 |
1995年 | 25篇 |
1994年 | 27篇 |
1993年 | 33篇 |
1992年 | 74篇 |
1991年 | 58篇 |
1990年 | 51篇 |
1989年 | 47篇 |
1988年 | 42篇 |
1987年 | 49篇 |
1986年 | 34篇 |
1985年 | 42篇 |
1984年 | 32篇 |
1983年 | 24篇 |
1982年 | 17篇 |
1981年 | 23篇 |
1980年 | 14篇 |
1979年 | 15篇 |
1978年 | 14篇 |
1973年 | 12篇 |
1972年 | 11篇 |
1971年 | 11篇 |
1968年 | 10篇 |
1967年 | 12篇 |
排序方式: 共有3715条查询结果,搜索用时 0 毫秒
71.
In several vascular inflammatory reactions (i.e. immunity and thrombosis) inflammatory mediators lead to the activation of vascular endothelial cells (EC). To date, a number of functional molecules induced on the surface of activated-EC have been identified. We report here that Globotetraosylceramide (Gb4), a glycosphingolipid expressed in EC, is a novel inducible molecule on EC activated by TNF-α. The cell surface expression of Gb4 is increased in a time-dependent manner under TNF-α stimulation, which shows distinct expression kinetics of major proteins induced by TNF-α on EC. MALDI-TOF-MS analysis revealed that the enhanced Gb4 predominantly contains C24:0 fatty acid in the ceramide moiety. Isolated caveolae/lipid raft-enriched detergent insoluble membrane domains in activated-EC predominantly contain this molecular species of Gb4. Gb4 containing C16:0 fatty acid in the ceramide moiety, which is known to constitute the major species of Gb4 in plasma, is also found as a major molecular species in EC. These observations indicate that Gb4, especially with very long fatty acid, is enhanced in EC during its inflammatory reaction, and suggest the potential utility of Gb4 as a biomarker for monitoring inflammation status of EC involving its related diseases. 相似文献
72.
Kenichiro Shirao Satoshi Okada Go Tajima Miyuki Tsumura Keiichi Hara Shin’ichiro Yasunaga Motoaki Ohtsubo Ikue Hata Nobuo Sakura Yosuke Shigematsu Yoshihiro Takihara Masao Kobayashi 《Human genetics》2010,127(6):619-628
Short-chain acyl-CoA dehydrogenase (SCAD) is a mitochondrial enzyme involved in the β-oxidation of fatty acids. Genetic defect of SCAD was documented to cause clinical symptoms such as progressive psychomotor retardation, muscle hypotonia, and myopathy in early reports. However, clinical significance of SCAD deficiency (SCADD) has been getting ambiguous, for some variants in the ACADS gene, which encodes the SCAD protein, has turned out to be widely prevailed among general populations. Accordingly, the pathophysiology of SCADD has not been clarified thus far. The present report focuses on two suspected cases of SCADD detected through the screening of newborns by tandem mass spectrometry. In both subjects, compound heterozygous mutations in ACADS were detected. The mutated genes were expressed in a transient gene expression system, and the enzymatic activities of the obtained mutant SCAD proteins were measured. The activities of the mutant SCAD proteins were significantly lower than that of the wild-type enzyme, confirming the mechanism underlying the diagnosis of SCADD in both subjects. Moreover, the mutant SCAD proteins gave rise to mitochondrial fragmentation and autophagy, both of which were proportional to the decrease in SCAD activities. The association of autophagy with programed cell death suggests that the mutant SCAD proteins are toxic to mitochondria and to the cells in which they are expressed. The expression of recombinant ACADS-encoded mutant proteins offers a technique to evaluate both the nature of the defective SCAD proteins and their toxicity. Moreover, our results provide insight into possible molecular pathophysiology of SCADD. 相似文献
73.
Matsuyama S Nagata N Shirato K Kawase M Takeda M Taguchi F 《Journal of virology》2010,84(24):12658-12664
The distribution of the severe acute respiratory syndrome coronavirus (SARS-CoV) receptor, an angiotensin-converting enzyme 2 (ACE2), does not strictly correlate with SARS-CoV cell tropism in lungs; therefore, other cellular factors have been predicted to be required for activation of virus infection. In the present study, we identified transmembrane protease serine 2 (TMPRSS2), whose expression does correlate with SARS-CoV infection in the upper lobe of the lung. In Vero cells expressing TMPRSS2, large syncytia were induced by SARS-CoV infection. Further, the lysosome-tropic reagents failed to inhibit, whereas the heptad repeat peptide efficiently inhibited viral entry into cells, suggesting that TMPRSS2 affects the S protein at the cell surface and induces virus-plasma membrane fusion. On the other hand, production of virus in TMPRSS2-expressing cells did not result in S-protein cleavage or increased infectivity of the resulting virus. Thus, TMPRSS2 affects the entry of virus but not other phases of virus replication. We hypothesized that the spatial orientation of TMPRSS2 vis-a-vis S protein is a key mechanism underling this phenomenon. To test this, the TMPRSS2 and S proteins were expressed in cells labeled with fluorescent probes of different colors, and the cell-cell fusion between these cells was tested. Results indicate that TMPRSS2 needs to be expressed in the opposing (target) cell membrane to activate S protein rather than in the producer cell, as found for influenza A virus and metapneumoviruses. This is the first report of TMPRSS2 being required in the target cell for activation of a viral fusion protein but not for the S protein synthesized in and transported to the surface of cells. Our findings suggest that the TMPRSS2 expressed in lung tissues may be a determinant of viral tropism and pathogenicity at the initial site of SARS-CoV infection. 相似文献
74.
75.
Takahashi Miyuki Takasugi Toshiyuki Kawakami Arisa Wei Ran Ando Kanae Ohshima Toshio Hisanaga Shin-ichi 《Neurochemical research》2022,47(9):2773-2779
Neurochemical Research - Valproic acid (VPA) is a drug used for the treatment of epilepsy, seizures, migraines, and bipolar disorders. Cyclin-dependent kinase 5 (Cdk5) is a Ser/Thr kinase activated... 相似文献
76.
Yokoro M Suzuki M Yatani M Yamashita H Takahashi Y Tsuji H Kimoto M 《Bioscience, biotechnology, and biochemistry》2012,76(2):400-403
We produced a monoclonal antibody (mAb) against N(G),N(G)-dimethyl-L-arginine (asymmetric dimethylarginine: ADMA), an endogenous competitive inhibitor of nitric oxide synthase (NOS), and developed an enzyme-linked immunosorbent assay (ELISA). The competitive ELISA method using the mAb determined 5 nM-100 nM ADMA, and ADMA levels in human plasma and urine were found to be 0.78 μM and 51.3 μmol/g of creatinine respectively. 相似文献
77.
Kurokawa K Kim MS Ichikawa R Ryu KH Dohmae N Nakayama H Lee BL 《Journal of bacteriology》2012,194(13):3299-3306
Bacterial lipoproteins are believed to exist in only one specific lipid-modified structure, such as the diacyl form or the triacyl form, in each bacterium. In the case of Staphylococcus aureus, recent extensive matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry analysis revealed that S. aureus lipoproteins exist in the α-aminoacylated triacyl form. Here, we discovered conditions that induce the accumulation of diacyl lipoproteins that lack α-aminoacylation in S. aureus. The accumulation of diacyl lipoproteins required a combination of conditions, including acidic pH and a post-logarithmic-growth phase. High temperatures and high salt concentrations additively accelerated the accumulation of the diacyl lipoprotein form. Following a post-logarithmic-growth phase where S. aureus MW2 cells were grown at pH 6, SitC lipoprotein was found almost exclusively in its diacyl structure rather than in its triacyl structure. This is the first report showing that the environment mediates lipid-modified structural alterations of bacterial lipoproteins. 相似文献
78.
79.
Naoyuki Okita Miyuki Yoshimura Kazuhito Watanabe Shota Minato Yuki Kudo Yoshikazu Higami Sei-ichi Tanuma 《Biochimica et Biophysica Acta (BBA)/General Subjects》2013
Background
CHK1 is an important effector kinase that regulates the cell cycle checkpoint. Previously, we showed that CHK1 is cleaved in a caspase (CASP)-dependent manner during DNA damage-induced programmed cell death (PCD) and have examined its physiological roles.Methods and results
In this study, we investigated the behavior of CHK1 in PCD. Firstly, we found that CHK1 is cleaved at three sites in PCD, and all cleavages were inhibited by the co-treatment of a pan-CASP inhibitor or serine protease inhibitors. We also showed that CHK1 is cleaved by CASP3 and/or CASP7 recognizing at 296SNLD299 and 348TCPD351, and that the cleavage results in the enhancement of CHK1 kinase activity. Furthermore, as a result of the characterization of cleavage sites by site-directed mutagenesis and an analysis performed using deletion mutants, we identified 320EPRT323 as an additional cleavage recognition sequence. Considering the consensus sequence cleaved by CASP, it is likely that CHK1 is cleaved by non-CASP family protease(s) recognizing at 320EPRT323. Additionally, the cleavage catalyzed by the 320EPRT323 protease(s) markedly and specifically increased when U2OS cells synchronized into G1 phase were induced to PCD by cisplatin treatment.Conclusion
CHK1 cleavage is directly and indirectly regulated by CASP and non-CASP family proteases including serine protease(s) and the “320EPRT323 protease(s).” Furthermore, 320EPRT323 cleavage of CHK1 occurs efficiently in PCD which is induced at the G1 phase by DNA damage.General significance
CASP and non-CASP family proteases intricately regulate cleavage for up-regulation of CHK1 kinase activity during PCD. 相似文献80.
Chihiro Minatsuki Nobutake Yamamichi Takeshi Shimamoto Hikaru Kakimoto Yu Takahashi Mitsuhiro Fujishiro Yoshiki Sakaguchi Chiemi Nakayama Maki Konno-Shimizu Rie Matsuda Satoshi Mochizuki Itsuko Asada-Hirayama Yosuke Tsuji Shinya Kodashima Satoshi Ono Keiko Niimi Toru Mitsushima Kazuhiko Koike 《PloS one》2013,8(7)